Background: The Directive 2001/20/EC was an important first step towards consistency in the requirements and processes for clinical trials across Europe. However, by applying the same rules to all types of drug trials and transposing the Directive’s principles into pre-existing national legislations, the Directive somewhat failed to meet its facilitation and harmonisation targets. In the field of ethics, the Directive 2001/20/EC conditioned the way of understanding and transposing the “single opinion” process in each country. This led to a situation in which two models of research ethics committees organisation systems exist, being the model in which the “single opinion” is considered to be the decision made by a single ethics committee more effective and simpler in terms of administrative and logistic workload.
Method: A survey was conducted in 10 European countries. Members of the European Clinical Research Infrastructures Network working party number 1, with expertise in the field of ethics, responded.
Results: There is a major heterogeneity in the composition of ethics committees among the surveyed countries based on the number of members, proportion of experts versus lay members and expertise of the scientific members. A harmonised education of the ethics committees’ membership based in common curricula is recommended by the majority of countries.
Conclusions: Despite the efforts for harmonisation of the European Clinical Trial Directive, from an ethical point of view, there remains a plurality of ethics committees' systems in Europe. It is important to comprehend the individual national systems to understand the problems they are facing.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Funding ECRIN is a project funded by the EU Sixth and Seventh Framework Programmes.
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Non-equivalent stringency of ethical review in the Baltic States: a sign of a systematic problem in Europe?
- Ethics Committee or Community? examining the identity of Czech Ethics Committees in the period of transition
- Education of ethics committee members: experiences from Croatia
- Legislative regulation and ethical governance of medical research in different European Union countries
- Why doctors use or do not use ethics consultation
- ‘The ethics approval took 20 months on a trial which was meant to help terminally ill cancer patients. In the end we had to send the funding back’: a survey of views on human research ethics reviews
- New governance arrangements for research ethics committees: is facilitating research achieved at the cost of participants’ interest
- Preventing ethics conflicts and improving healthcare quality through system redesign
- Has the European Clinical Trials Directive been a success?
- Post-trial access to study medication: a Brazilian e-survey with major stakeholders in clinical research